検索結果
-
PLUG 2024Q1 result 【Q1】 ×? EPS ‐0.46(予想 -0.33) (‐0.46と-0.33はnon-GAPPでそろってるのかどうかは知らん) × Rev 120M (予想 157.58M) 【Q2ガイダンス】 Rev ?(予想 202.19M) 【2024年通年ガイダンス】 Rev ?(予想 985.69M) Restructuring, Impairment, and Other Provisions: As a result of the evolving market dynamics, Plug mobilized certain cost down actions in the first quarter. This included headcount reduction, rooftop consolidation, and non-payroll cost downs. This resulted in restructuring costs of ~$6 million in the quarter. In addition, given certain business dynamics, the Company wrote down certain assets which resulted in non-cash charges recorded in Q1 2024 of ~$40 million. Further details regarding these charges are provided in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024. ここってガイダンスだすの?まあrestructuringは進めてるみたいだけど。
-
A floating exchange rate can be classified as free floating if intervention occurs only exceptionally, aims to address disorderly market conditions, and if the authorities have provided information or data confirming that intervention has been limited to at most three instances in the previous six months, each lasting no more than three business days. If the information or data required are not available to the IMF staf/ the arrangement will be classified as floating.
-
被験者リクルートメント開始~同、治験薬投薬開始のニュースも もうすぐやろ!(^^)! Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma First Posted : April 1, 2024 ponsor: Weill Medical College of Cornell University Collaborators: Merck Sharp & Dohme LLC Oncolys BioPharma Inc Information provided by (Responsible Party): Weill Medical College of Cornell University 実験的:OBP-301 とペムブロリズマブ すべての参加者は、OBP-301 の腫瘍内注射を 4 回受け、各注射は約 2 週間間隔で行われます。すべての参加者は、疾患が進行するまで、または最大 2 年間、6 週間ごとにペムブロリズマブの注入も受けます。 薬:OBP-301 2 週間ごとに 2 週間ごとに 2×10 (12) 個のウイルス粒子を腫瘍内に投与し、研究の 1 日目から合計 4 回の注射 ほかの名前: スラタデノツレブ 薬:ペムブロリズマブ 研究の 4 日目から 6 週間ごとに 400 mg の IV を投与し、最長 2 年間投与 ほかの名前: キイトルーダ ...
-
がっちりマンデー アドバンスドメディアを紹介してます。 ーAmiVoice Communication Suite provided by コラボスは、日本国内唯一の音声認識専門企業である株式会社アドバンスト・メディアが提供する世界最高性能を誇る音声認識エンジンを用いた、クラウド型コールセンター向け音声認識サービスです。
-
#VaccineGenocide | If freely administered #COVID19 vaccines or others were truly lifesaving and so called Govts. truly bother about saving human lives, the lifesaving drugs for cancer, AIDS, diabetes, etc. should’ve been provided free of cost, whereas only poison is given freely. 〈Googleによる英語からの翻訳〉 #VaccineGenocide | 無料で投与される#COVID19ワクチンなどが本当に命を救うものであり、いわゆる政府が本当に人命を救うことに関心があるのであれば、癌、エイズ、糖尿病などの命を救う薬は無料で提供されるべきであり、無料で提供されるのは毒物だけです。 ⬆️ なるほどねーーー
$BTBT Bit Digit…
2024/05/16 05:38
$BTBT Bit Digital reports Q1 GAAP EPS 43c, consensus 1c Reports Q1 revenue $30.3M, consensus $27.73M. "Our First Quarter 2024 results represent a strong start to the year with revenue growing by more than 250% and GAAP Net Income in excess of $50 million. The primary drivers for the improved performance were the commencement of our Bit Digital AI business and a higher realized bitcoin price. We were well prepared for the halving which occurred in April 2024. Our balance sheet remains a core strength with over $160 million of total liquidity as of March 31, 2024, zero debt, and a growing revenue stream that is not correlated to the economics of bitcoin mining. While we continue to evaluate the post-halving bitcoin mining landscape, our goal of reaching 6.0 EH/s this year remains intact. We are actively engaged in discussions for both incremental hosting opportunities and potential acquisitions. We continue to believe that capital allocation optionality provided by our complementary business lines is a key differentiator for our Company. We are actively evaluating a number of growth opportunities, both organic and inorganic, across each of our business lines. We are in the late stages of finalizing an agreement to double the size of the GPU fleet for our anchor client and our negotiations with prospective clients are progressing well. Our target of reaching a $100 million annualized revenue run-rate by year-end for this segment remains intact."